Market closed
Xenetic Biosciences Inc./$XBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
Ticker
$XBIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
2
Website
XBIO Metrics
BasicAdvanced
$3.7M
-
-$2.57
2.18
-
Price and volume
Market cap
$3.7M
Beta
2.18
52-week high
$4.12
52-week low
$2.20
Average daily volume
7.6K
Financial strength
Current ratio
7.366
Quick ratio
6.895
Management effectiveness
Return on assets (TTM)
-30.02%
Return on equity (TTM)
-50.12%
Valuation
Price to revenue (TTM)
1.486
Price to book
0.62
Price to tangible book (TTM)
0.62
Price to free cash flow (TTM)
-1.318
Growth
Revenue change (TTM)
-1.56%
Earnings per share change (TTM)
-5.03%
3-year revenue growth (CAGR)
29.15%
3-year earnings per share growth (CAGR)
-22.37%
XBIO News
AllArticlesVideos
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Accesswire·7 days ago
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Accesswire·3 weeks ago
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Xenetic Biosciences Inc. stock?
Xenetic Biosciences Inc. (XBIO) has a market cap of $3.7M as of April 16, 2025.
What is the P/E ratio for Xenetic Biosciences Inc. stock?
The price to earnings (P/E) ratio for Xenetic Biosciences Inc. (XBIO) stock is 0 as of April 16, 2025.
Does Xenetic Biosciences Inc. stock pay dividends?
No, Xenetic Biosciences Inc. (XBIO) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Xenetic Biosciences Inc. dividend payment date?
Xenetic Biosciences Inc. (XBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Xenetic Biosciences Inc.?
Xenetic Biosciences Inc. (XBIO) has a beta rating of 2.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.